CC
ANRO icon

Commodore Capital’s Alto Neuroscience ANRO Stock Holding History

Commodore Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.2M Buy
2,723,196
+900,000
+49% +$16.7M 3.54% 11
2025
Q4 		$32.5M Buy
+1,823,196
New +$23M 2.16% 21

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Commodore Capital's ANRO Position: Q1 2026 in Review

Commodore Capital increased its Alto Neuroscience (ANRO) stake by 49% in Q1 2026, buying an estimated $16.7M and bringing the position to 2,723,196 shares worth $61.2M. The position accounts for 3.54% of the portfolio, ranked #11.

Commodore Capital first reported a position in ANRO in Q4 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Commodore Capital held 2,723,196 shares of Alto Neuroscience worth $61.2M as of Q1 2026.
  • Commodore Capital bought 900,000 Alto Neuroscience shares in Q1 2026, an estimated $16.7M.
  • Alto Neuroscience made up 3.54% of Commodore Capital's portfolio in Q1 2026, its #11 holding.
  • Commodore Capital first reported a position in Alto Neuroscience in Q4 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.